Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007 May 15; 109(10):2077-82.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.